Drugs / OXY111A
OXY111A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02528526 | Feb 2014 → Dec 2016 | cholangiocarcinoma, colorectal neoplasm, hepatocellular carcinoma, pancreatic neoplasm | University of Zurich | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OXY111A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02528526 ↗ |
| Known as | ITPP | “The novel antihypoxic molecule myo-inositoltrispyrophosphate (ITPP, OXY111A) acts as an allosteric effector of hemoglobin and promotes normoxia in hypoxic tumors.” PMID 27756258 ↗ Oct 2016 |
| Known as | myo-inositoltrispyrophosphate | “The novel antihypoxic molecule myo-inositoltrispyrophosphate (ITPP, OXY111A) acts as an allosteric effector of hemoglobin and promotes normoxia in hypoxic tumors.” PMID 27756258 ↗ Oct 2016 |
| Route | Intravenous | “OXY111A intravenous infusion” NCT02528526 ↗ |